Nautilus Biotechnology announced its Q3 2026 financial results, reporting $0.2 million in revenue mainly from grants and early access services, and a net loss of $15.6 million. The company highlighted progress in its proteome analysis platform, including a key publication and oncology assay developments, reinforcing confidence in its technology and roadmap. Nautilus also joined a major ARPA-H funded research consortium to study proteoforms linked to Alzheimer’s and cancer, expecting up to $6 million in funding. The company plans to launch its Voyager platform by mid-2027, aiming to expand its proteoform assay portfolio.
Nautilus Biotechnology's Q3 2026 results provide context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 27, 2026 17:02 WIB: Of 150 priced US health stocks, 60 rose and 78 fell. ALMS was priced at USD 6.70 with a 1-day change of +2.92%, ACAD at USD 20.28 with 0% Sell / 100% Buy order activity, and TNGX at USD 21.61 with 14% Sell / 86% Buy order activity.
Eviden, part of Atos Group, has introduced ASTRA-LAS, a tactical decision-support solution designed to aid naval officers in complex maritime environments. The system uses operational data and AI to enhance situational awareness, reduce cognitive loa...
Eviden, part of Atos Group, has introduced ASTRA-LAS, a new AI-powered tactical assistant designed to support naval operations by providing enhanced visualizations, automated analyses, and mission-specific recommendations. This system helps naval off...
Investec Bank plc, acting as joint broker for Pollen Street Group Limited, disclosed share transactions on October 26, 2026. The bank purchased and sold 20,765 ordinary shares at prices ranging from 929 to 935 per share. There were no derivative tran...
Investec Bank Plc, acting as financial adviser to DBAY Advisors Limited, purchased 50,000 ordinary shares of Logistics Development Group plc on October 26, 2026, at a price of 21.5 per share. This transaction was disclosed under Rule 8.5 of the Takeo...
Investec Bank plc, acting as joint broker to Gamma Communications Plc, disclosed public dealings involving the purchase and sale of 166,789 ordinary shares on October 26, 2026. The transactions were conducted at prices around 1090-1091 pence per shar...
